• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Reversing the effects of the new anti-clotting drugs
The oral anticoagulant warfarin (Coumadin) became available for prescription in 1954. This anti-clotting drug commanded national attention when President Dwight Eisenhower received the drug as part of his treatment following a heart attack. No other oral anticoagulant was successfully developed and marketed in the United States until 2010. Warfarin is a dangerous drug. Along with insulin, it is responsible for the most emergency hospitalizations due to adverse drug reactions. Whereas insulin causes low blood sugar, warfarin is notorious for the complication of major bleeding. Warfarin is plagued by hundreds of drug-drug an...
Source: New Harvard Health Information - December 9, 2015 Category: Consumer Health News Authors: Samuel Z. Goldhaber, MD Tags: Drugs and Supplements Health Heart Health Hypertension and Stroke anti-clotting coumadin deep-vein-thrombosis DVT Source Type: news

Impact of NOACs on Ischemic Stroke Severity in AF Impact of NOACs on Ischemic Stroke Severity in AF
Can the use of non-vitamin K-dependent oral anticoagulants prior to stroke onset in patients with atrial fibrillation reduce the severity of stroke, if ischemic stroke should occur?Europace
Source: Medscape Today Headlines - May 11, 2018 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Study: Fish Oil Doesn ’ t Seem To Prevent Heart Problems
This study is consistent with earlier trials. The US Food and Drug Administration approved the fish oil-based drug Vascepa for heart attack and stroke prevention in 2019. Nissen hopes the FDA will take a look at these studies and reconsider that decision. “But it’s hard to get something undone once the genie gets out of the bottle,” he said. An editorial in the journal that accompanies the study written by Dr. Gregory Curfman, assistant professor of medicine at Harvard Medical School, also suggested the FDA should require a postmarketing clinical trial of a high-dose of fish oil, such as Vascepa, vs. corn...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - November 16, 2020 Category: Consumer Health News Authors: CBS Boston Tags: Boston News Health Syndicated CBSN Boston CNN fish oil Source Type: news

New Oral Anticoagulant Drugs: A Guide From European Society Of Cardiology
A practical guide on the use of the new oral anticoagulants (NOACs) has been produced by the European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC). A guide was needed to summarise existing information on different drugs, to answer clinical questions that fall outside what drug companies can legally answer, and to make distinctions between the different drugs. ESC guidelines on atrial fibrillation recommend the NOACs as preferable to vitamin K antagonists for stroke prevention in patients with non-valvular atrial fibrillation...
Source: Health News from Medical News Today - April 30, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news

New Oral Anticoagulants in Non-Valvular Atrial FibrillationNew Oral Anticoagulants in Non-Valvular Atrial Fibrillation
Learn more about new oral anticoagulants as an alternative for vitamin K antagonists to prevent stroke. European Heart Journal
Source: Medscape Today Headlines - August 2, 2013 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Apixaban vs Warfarin in Patients With Atrial FibrillationApixaban vs Warfarin in Patients With Atrial Fibrillation
Are the rates of stroke/systemic embolism and major bleeding lower among patients assigned to apixaban -- irrespective of prior vitamin K antagonist use? American Heart Journal
Source: Medscape Today Headlines - November 7, 2013 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Non-Vitamin K Antagonist Anticoagulants and Atrial FibrillationNon-Vitamin K Antagonist Anticoagulants and Atrial Fibrillation
Find out more about AF risk assessment along with NOAC phase III clinical trials for the prevention of stroke and more. American Journal of Cardiovascular Drugs
Source: Medscape Today Headlines - November 11, 2015 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news